Abstract
Background: Presence of dementia is a contraindication for DBS treatment of Parkinson's disease. Recent evidence suggests that borderline cognitive function, as measured with a common screening measure, the Mattis Dementia Rating Scale, has a negative impact on quality of life (QoL) after DBS of the STN. Methods: We attempted to replicate and extend this finding in a larger group of patients with a wider range of preoperative global cognitive performance. Results: Our data indicate that performance on the screening measure is not associated with QoL or medical outcomes, even with scores well below the cutoff for identifying dementia. Conclusions: This cognitive screening measure lacks sufficient sensitivity to warrant its use in predicting which patients will show QoL benefit from DBS.
Original language | English (US) |
---|---|
Pages (from-to) | 1279-1283 |
Number of pages | 5 |
Journal | Movement Disorders |
Volume | 30 |
Issue number | 9 |
DOIs | |
State | Published - Aug 1 2015 |
Bibliographical note
Publisher Copyright:© 2015 International Parkinson and Movement Disorder Society
Keywords
- Parkinson's disease
- cognition
- deep brain stimulation
- outcome research
- quality of life